A New Drug Target for Type 2 Diabetes

Islet Amyloid Polypeptide is not a Target Antigen for CD8+ T-Cells in Type 2 Diabetes

Background: Type 2 diabetes (T2D) is a chronic metabolic disorder in which beta-cells are destroyed. The islet amyloid polypeptide (IAPP) produced by beta-cells has been reported to influence beta-cell destruction. Objective: To evaluate if IAPP can act as an autoantigen and therefore, to see if CD8 + T-cells specific for this protein might be present in T2D patients. Methods: Peripheral blood ...

Imeglimin: A Potential New Multi-Target Drug for Type 2 Diabetes

Imeglimin is a novel agent currently in development to treat type 2 diabetes. Laboratory studies have demonstrated that it has the potential to impact the three main pathophysiologic components of type 2 diabetes: impaired glucose uptake by muscle tissue, excess hepatic gluconeogenesis, and increased beta-cell apoptosis. Preliminary human studies that have been published within the last 2 years...

NEW DRUG APPROVALS Xultophy for Type-2 Diabetes

NEW DRUG APPROVALS Xultophy for Type-2 Diabetes The FDA has approved Xultophy 100/3.6 (insulin degludec 100 units/mL and liraglutide 3.6 mg/mL injection, Novo Nordisk). The product, a once-daily combination of Tresiba (insulin degludec injection) and Victoza (liraglutide injection), is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes that i...

islet amyloid polypeptide is not a target antigen for cd8+ t-cells in type 2 diabetes

background: type 2 diabetes (t2d) is a chronic metabolic disorder in which beta-cells are destroyed. the islet amyloid polypeptide (iapp) produced by beta-cells has been reported to influence beta-cell destruction. objective: to evaluate if iapp can act as an autoantigen and therefore, to see if cd8 + t-cells specific for this protein might be present in t2d patients. methods: peripheral blood ...

A new predictor for type 2 diabetes?